Considering primary outcomes, genetically predicted perturbation of the LPL pathway through APOC3, ANGPTL4, and LPL was associated with lower risk of CAD and T2D (Figure 2A; Supplemental Tables 3-4) after adjusting for multiple testing. This evidence concerns the gene ANGPTL4 and coronary artery disorder.